A main problem in the treatment of advanced cancers is the incertitude at which we predict how individual patients will respond to DNA-damaging agents, especially on the long run. Despite a wealth of genomic information, “more-is-better” and “one-size-fits-all” remain the principles according to which DNA-damaging agents are administered.
We seek applications from individuals to test the potential of the very long-term legacy that DNA-damage entails on a cell – genomic instability – as new biomarker of DNA damage response. The position is fully funded through an NCI R00 awarded to Dr. Andor and an R35 NCI Outstanding Investigator Award awarded to Dr. Flores. The postdoctoral researcher will be co-mentored by Drs. Andor and Flores.
Position Highlights: This Postdoc will be part of a multi-disciplinary team in the Departments of Integrated Mathematical Oncology (IMO) and Molecular Oncology, where wet- and dry-lab components of in-vitro and in-vivo experiments are seamlessly integrated to meet the project’s central challenge: quantifying the growth rates of coexisting tumor clones.
The Ideal Candidate: extensive experience working in both, in-vitro and in-vivo systems, in particular with GEMMs. has interest in learning basics of programming to trace long-term trends in the clonal evolution of cell populations.
Responsibilities: communicate with computer scientists and mathematicians. will expose cell lines and mouse models of cancer to DNA damaging agents and quantify drug-induced changes in their clonal composition from different perspectives, including their transcriptome and histopathology.
Credentials and Qualifications: MD or PhD in Cancer Biology, Genetics, Pharmacology or Molecular Biology. This position brings a unique opportunity to be co-mentored by multiple investigators at the forefront of this multidisciplinary field, in an environment where experimental and computational domains interact like clockwork. It includes funded travel to attend research conferences.
Interested applicants should send a cover letter , current CV, contact information for three references and a brief personal statement describing their perspective on the co-evolution of tumor cells and therapy to Drs. Flores and Andor at Elsa.Flores@Moffitt.org and Noemi.Andor@Moffitt.org.
Moffitt Cancer Center is an Equal Opportunity/Affirmative Action Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, or protected veteran or disabled status. We seek candidates whose skills, and personal and professional experience, have prepared them to contribute to our commitment to diversity and excellence.